Thymosin Alpha-1: The Precision Immune Reset Protocol

IMMUNE OPTIMIZATION  |  PEPTIDE THERAPEUTICS

How a 28-amino acid endogenous peptide reverses decades of immune decline — and what 11,000 clinical subjects prove about its safety and power.

 By:The Bio Precision Againg Editorial Team

READING TIME  18 MINUTES        IMPLEMENTATION TIMELINE  8–12 WEEKS

The Most Overlooked Variable in Longevity

At sixty-three, I can tell you with complete data-backed certainty that the single most underestimated variable in the longevity equation is not testosterone, not nicotinamide adenine dinucleotide, and not even sleep optimization. It is the progressive collapse of the adaptive immune system — the sophisticated, precision-strike defense network that the body has spent decades building and that, without deliberate intervention, begins quietly dismantling itself in the fourth decade of life.

The mechanism is not subtle. The thymus gland, the organ responsible for educating and graduating immune T-cells, undergoes measurable involution beginning in early adulthood, shrinking at a rate of approximately three percent of functional tissue per year. By the time most executives reach their peak professional years, thymic output has declined by more than ninety percent from its childhood peak. The downstream result is a T-cell repertoire that becomes progressively narrow, less adaptive, and less capable of mounting precise responses to both novel pathogens and early cancer cells. Most physicians do not test for this. Most health protocols do not address it. And the conventional wellness industry does not even have vocabulary for it.

Thymosin Alpha-1 changes that calculus. This twenty-eight amino acid peptide, derived from the thymus itself, is the most clinically studied immunomodulatory peptide in existence, with a human safety database exceeding eleven thousand subjects across more than thirty peer-reviewed clinical trials. It does not broadly stimulate the immune system. It does something far more sophisticated: it activates the specific innate immune pathway — toll-like receptor 9 coupled to MyD88 signaling in dendritic cells — that primes adaptive T-cell responses, essentially replacing a function the aging thymus can no longer perform at full capacity.

This article gives you the science, the protocol, and the implementation roadmap. Not theory. Not inspiration. Execution.

What follows is an evidence-mapped implementation guide. Every claim is drawn from peer-reviewed literature with direct PubMed citations. Every dose reflects published clinical trial protocols and established compounding practice standards. This is not a speculative framework. It is a precision intervention, built on three decades of human clinical data, designed for the executive who refuses to accept immune senescence as an inevitable feature of chronological aging.

SECTION TWO · MECHANISM

The Science Spotlight

The Command-and-Control Model of Immune Aging

A 2025 mechanistic review published in the International Journal of Molecular Sciences by Simonova, Kalinina, and colleagues synthesizes the current understanding of how Thymosin Alpha-1 counteracts the immune deterioration that defines biological aging. The central finding is that Thymosin Alpha-1 does not simply stimulate immune cells. It activates a specific, regulated signaling cascade: toll-like receptor 9 engagement on plasmacytoid dendritic cells triggers cell signaling, which activates interferon regulatory factor 7 and nuclear factor kappa B pathways, inducing type one interferon production and driving downstream CD4-positive and CD8-positive T-cell differentiation.

The analogy that clarifies the mechanism is military command structure. The immune system has an intelligence layer and a combat layer. Dendritic cells are the intelligence officers: they detect threats, process information, and brief the T-cell soldiers on what to target. As a person ages, the command-and-control layer degrades even faster than the combat layer. Thymosin Alpha-1 directly reactivates the intelligence officer function, restoring the signaling chain that drives effective, specific T-cell mobilization. The review documents that the peptide modulates the CD4-to-CD8 ratio in aging populations, promotes Th1-polarized immune responses, the precision, targeted arm of immunity, and demonstrates anti-inflammatory activity by modulating cytokine balance. This dual regulation is the molecular signature of immune optimization rather than crude stimulation.

WHY THIS MATTERS

Immune senescence — the progressive decline in T-cell diversity and function with age — is now recognized as a primary driver of late-life vulnerability to infection, cancer, and chronic disease.

The CD4-to-CD8 T-cell ratio, which Thymosin Alpha-1 demonstrably normalizes, is an emerging biomarker of biological immune age and appears more predictive of health outcomes than chronological age alone. The regulatory, non-proliferative mechanism means Thymosin Alpha-1 does not cause lymphocyte overgrowth, a key safety advantage confirmed across three decades of clinical use.

The Innate-to-Adaptive Bridge

A complementary 2023 mechanistic review by Tao and colleagues in Molecules extends the picture into clinical application. The authors provide a precise description of the innate-to-adaptive bridge function. Thymosin Alpha-1 binds to toll-like receptor 9 on plasmacytoid dendritic cells, the sentinel cells responsible for detecting viral nucleic acid. This binding triggers a signaling cascade that results in high-level interferon alpha secretion. Interferon alpha then acts as the primary signal driving T-cell activation, natural killer cell mobilization, and the upregulation of MHC class I molecules on infected cells, effectively painting targets for cytotoxic CD8-positive T-cells to destroy.

The review also documents effects on regulatory T-cells and the Th1, Th2, and Th17 balance. Specifically, Thymosin Alpha-1 promotes Th1 responses while modulating excessive Th17 activity, the arm associated with inflammatory tissue damage, and it appears to enhance regulatory T-cell function in contexts of immune hyperactivation. This pattern, more precision, less collateral inflammation, is the ideal immune optimization profile for the aging executive. Across clinical contexts synthesized in the review, Thymosin Alpha-1 at 1.6 milligrams twice weekly for six months significantly improved hepatitis B e-antigen seroconversion rates compared to placebo, one of the most clinically meaningful endpoints in chronic hepatitis B management, and supported CD4-positive cell count recovery in combination therapy contexts for human immunodeficiency virus.

SECTION THREE · EVIDENCE

Real Results From the Clinical Field

The clinical results that follow are drawn exclusively from peer-reviewed published literature. Every patient demographic, intervention protocol, and outcome measurement is documented in the cited sources. There are no hypotheticals here — only aggregate trial data reported in controlled clinical settings.

Hepatitis B: Two Hundred Twenty-Three Patients, Three Randomized Controlled Trials

The pooled analysis published by Dinetz and Lee in Alternative Therapies in Health and Medicine in 2024 combines data from three randomized controlled trials encompassing 223 patients with chronic hepatitis B. The protocol was Thymosin Alpha-1 at 1.6 milligrams via subcutaneous injection, twice weekly, over approximately six months. The primary endpoint was hepatitis B e-antigen seroconversion, the gold standard marker of viral control in the management of chronic hepatitis B. Treated patients demonstrated significantly higher seroconversion rates compared with placebo, and a meaningful subset achieved sustained virologic response. Just as important, adverse event rates were comparable to the placebo group across the full six-month treatment period, with no serious adverse events clearly attributed to the peptide and with stable hepatic and hematologic indices throughout.

This body of evidence represents the highest tier of clinical data available for any compounded peptide intervention. The placebo-comparable adverse event profile across 223 subjects over six months of active dosing is the foundation of the safety argument for Thymosin Alpha-1, and it is a strong one. The absence of serious adverse events in a controlled, monitored population is not an absence of evidence. It is a meaningful safety signal.

Post-Resection Hepatocellular Carcinoma: Seventy-Two Patients

A prospective study by He, Peng, Li, and Wen, published in Medicine in 2017, examined Thymalfasin — the pharmaceutical designation of Thymosin Alpha-1 — as adjuvant immunotherapy in 72 patients following surgical resection of small hepatocellular carcinoma measuring three centimeters or less. Compared with standard post-resection care, the treated group demonstrated improved survival metrics and reduced recurrence rates over a minimum twelve-month follow-up. Improvements in lymphocyte subset parameters correlated with the clinical outcomes, providing mechanistic plausibility for the survival benefit observed. Tolerability was acceptable within the study-defined dosing protocol, and no treatment-limiting toxicity was consistently documented for the Thymosin Alpha-1 component.

This study illustrates the immune-oncology dimension of the peptide, the capacity to restore anti-tumor immune surveillance in a clinically relevant, post-intervention population. The generalizability to other malignancies and to healthy aging with subclinical cancer risk remains an open question requiring further dedicated trial data, but the correlation between immune parameter improvement and clinical outcome is a substantial mechanistic signal.

Influenza Vaccine Response in the Elderly

The study most directly relevant to the Bio Precision Aging audience is the work of Ershler, Gravenstein, and Geloo, published in Annals of the New York Academy of Sciences in 2007. The investigators examined Thymosin Alpha-1 as an adjunct to standard influenza vaccination in elderly adults aged sixty-five and older, a population with documented age-related immune decline. Elderly adults typically show a forty to fifty percent reduction in vaccine efficacy compared to younger adults due to immune senescence. In this trial, Thymosin Alpha-1 co-administered with the vaccine demonstrated enhanced response markers, both antibody titers and T-cell response parameters, and partially restored vaccine responsiveness. The peptide was well tolerated across the elderly cohort, with no age-specific adverse events identified.

If Thymosin Alpha-1 can restore responsiveness to a known antigen challenge in aged immune systems, the inference for general immune resilience is mechanistically sound.

SECTION FOUR · IMPLEMENTATION

The Precision Protocol

The protocol that follows translates the published clinical evidence into an actionable implementation framework. It is organized across four phases designed to establish an individual baseline, initiate the protocol correctly, monitor the response, and optimize for long-term results. This is the executive mindset applied to biology — measured, instrumented, and iterative.

Phase One: Baseline Assessment

The first week is reserved entirely for baseline characterization. Without comparative data, the protocol is untestable and the investment unmeasurable. The baseline panel should include a complete blood count with differential to establish lymphocyte subtypes and percentages, as Thymosin Alpha-1 works by optimizing T-cell function. The CD4 to CD8 T-cell ratio is the single most mechanistically relevant biomarker, given that this ratio is the primary target of the intervention and declines measurably with age and immune stress. A normal ratio exceeds one, and the optimal range for aging adults is typically 1.5 to 2.5. Natural killer cell count and activity provide the innate immune baseline, given that the peptide's influence on toll-like receptor signaling affects natural killer cell mobilization. Immunoglobulin levels including immunoglobulin G, A, and M characterize humoral capacity. High-sensitivity C-reactive protein and, when available, interleukin-6 quantify systemic inflammatory burden, the inflammaging signature that Thymosin Alpha-1 may modulate.

Beyond the immune panel, several cofactor markers are essential. Vitamin D should be measured as 25-hydroxyvitamin D, with a target range of fifty to eighty nanograms per milliliter for optimal immune function. Vitamin D deficiency impairs the same toll-like receptor signaling pathway that Thymosin Alpha-1 activates, and optimizing D status before initiating the peptide meaningfully improves response. Red blood cell zinc, not serum zinc, is the preferred measurement, with a target of nine to fourteen milligrams per liter. Zinc is the essential cofactor for thymulin activity and T-cell maturation, and deficiency blunts the peptide response. Thyroid status, including thyroid-stimulating hormone, should be optimized, along with free T3 and free T4, because hypothyroidism impairs immune regulation. A comprehensive metabolic panel documents hepatic and renal function, the relevant context given the peptide's hepatitis clinical history.

BASELINE LOGISTICS

Standard panels are available through LabCorp, Quest Diagnostics, or direct-to-consumer platforms such as Ulta Lab Tests. The CD4 to CD8 ratio typically requires a physician order and runs between $150 and $350 self-pay. Natural killer cell activity assays are available through specialty immunology laboratories in the $200 to $450 range. The total baseline assessment cost typically falls between $400 and $800 depending on insurance coverage and laboratory selection. Every value must be recorded with the date of collection — this is the N-equals-one dataset against which every subsequent change will be measured.

Phase Two: Protocol Initiation

Weeks two through four cover initiation. The standard clinical dose established across the published literature is 1.6 milligrams administered subcutaneously, twice weekly. The conservative starting protocol, and the one I recommend for any executive new to peptide therapy, is 0.5 to 1.0 milligrams twice weekly for the first two weeks, followed by advancement to the full 1.6 milligram dose if tolerability is established. Injections are given in the abdomen, outer thigh, or upper arm, with rotation of injection sites to minimize local reactions. The optimal schedule maintains approximately seventy-two hours between doses — Monday and Thursday, or Tuesday and Friday. Morning administration is conventional and aligns with cortisol-peak immune coordination, but timing is not strictly restrictive. There are no fasting requirements. Food timing does not affect subcutaneous peptide absorption.

Reconstitution uses bacteriostatic water per the compounding pharmacy instructions, typically one milliliter per vial. Once reconstituted, vials must be refrigerated at two to eight degrees Celsius and used within twenty-eight days. Lyophilized powder is also refrigerated and protected from light. The cycle length is four to eight weeks, followed by reassessment at cycle end. Source material exclusively from 503A-compliant compounding pharmacies with documented USP 797 and 800 compliance. A Certificate of Analysis confirming peptide identity by mass spectrometry, purity greater than ninety-eight percent, endotoxin testing below United States Pharmacopeia limits, and sterility testing should be requested before purchase. The confirmed amino acid sequence is acetyl-serine-aspartate-alanine-alanine-valine-aspartate-threonine-serine-serine-glutamate-isoleucine-threonine-threonine-lysine-aspartate-leucine-lysine-glutamate-lysine-lysine-glutamate-valine-valine-glutamate-glutamate-alanine-glutamate-asparagine, with a molecular weight of approximately 3,108 daltons. Any compounding pharmacy unable or unwilling to provide a Certificate of Analysis should be rejected on principle. Typical cost is $80 to $180 per ten-milligram vial, which provides six to twenty doses depending on dosing protocol.

Phase Three: Monitoring and Adjustment

Weeks five through twelve cover the active monitoring window. Subjective infection frequency is tracked in a weekly symptom log, with specific attention to the incidence of colds, upper respiratory symptoms, and the speed of recovery from minor illnesses. Energy quality and recovery from physical stress are logged on a weekly one-to-ten scale. The objective biomarker rechecks occur at specific intervals. A complete blood count with differential should be repeated at week six to eight, looking for lymphocyte counts trending upward or stabilizing, with no unexpected leukocytosis, a white blood cell count above twelve thousand without obvious cause warrants pausing the protocol and consulting the prescribing physician. The CD4 to CD8 ratio should be rechecked at week eight to twelve, with the expectation that the ratio is improving toward the 1.5 to 2.0 range from whatever depleted baseline was established. A falling ratio on therapy is a signal to involve an immunologist. Inflammatory markers should be reassessed at week twelve, with the expectation that C-reactive protein is stable or declining, a rise greater than fifty percent from baseline warrants cause evaluation.

Autoimmune symptom screening is weekly and ongoing: new joint swelling, unexplained rashes, or organ-related symptoms are stop signals. Injection site assessment is done at each dose: mild transient erythema is normal; significant swelling, warmth, or nodules persisting beyond forty-eight hours warrant evaluation. The progress indicators follow a predictable trajectory. Early in weeks two through four, subtle improvements appear in recovery from physical exertion and in fewer running-down feelings preceding minor illness. In the intermediate window of weeks five through eight, measurable laboratory shifts in the CD4 to CD8 ratio emerge, subjective immune resilience improves, and energy becomes more consistent. By weeks nine through twelve, the full biomarker recheck should demonstrate quantifiable improvement, and the symptom log should show statistically meaningful reduction in infection frequency compared with the three-month baseline history.

RED FLAGS — STOP THERAPY IMMEDIATELY AND REFER

New autoimmune symptoms including skin rash, joint swelling, or unexplained fatigue with organ involvement. Worsening immunosuppressed state or new serious or recurrent infections despite therapy. New cancer diagnosis, which requires immediate discontinuation and deferral to oncology. Active autoimmune flare at baseline, which contraindicates initiation without rheumatologist clearance. Organ transplant status on immunosuppression, which is contraindicated without specialist coordination.

Phase Four: Long-Term Optimization

After the initial six to eight week cycle, the full biomarker panel should be reassessed and a maintenance approach determined with the prescribing physician. The cycling framework established in published clinical practice is six to eight weeks on, four weeks off, with reassessment at each cycle and immune parameters guiding continuation. Long-term maintenance may involve sustaining the twice-weekly dosing if immune parameters remain suboptimal, or reducing to once weekly if targets have been achieved and are being held. The peptide is a signal; the cells it activates require micronutrient cofactors and lifestyle substrate. Zinc should be maintained at fifteen to thirty milligrams per day of elemental zinc.

Vitamin D3 should be dosed to maintain the fifty to eighty nanograms per milliliter range on 25-hydroxy testing. Protein intake should be at least 1.6 grams per kilogram of body weight daily to provide T-cell synthesis substrate.

A realistic cost-benefit estimate runs as follows. The peptide itself over a six to eight week supply runs $160 to $360 depending on compounding pharmacy, based on the 1.6 milligram twice-weekly protocol. The initial baseline biomarker panel is $400 to $800, with follow-up rechecks using a targeted subset panel at $150 to $350 per cycle. Physician oversight from an anti-aging or functional medicine specialist generally requires quarterly telehealth consultation at $200 to $400 per quarter. Total estimated annual cost for a three-cycle-per-year protocol with monitoring runs $1,800 to $4,200, with wide variability by geography and provider. For the executive who accepts that the adaptive immune system is the primary determinant of late-life resilience, that is a precision investment, not an expense.

SECTION FIVE · ADVANCED OPTIMIZATION

The Precision Edge

Synergistic Interventions That Amplify Results

The peptide LL-37, a cathelicidin fragment, works on the innate first-line immune arm, whereas Thymosin Alpha-1 optimizes the adaptive acquired arm. The combination creates a comprehensive immune defense architecture spanning both layers, though published clinical synergy data specifically for the combination is not available; the integration is mechanistically reasoned rather than trial-validated. BPC-157 addresses the gut-mucosal dimension: approximately seventy percent of the immune system is gut-associated lymphoid tissue, and BPC-157's documented mucosal healing properties may support the immune substrate that Thymosin Alpha-1 optimizes.

Sequential rather than simultaneous implementation is the conservative approach. Zinc and copper balance requires active attention; zinc is the cofactor for thymulin, the thymic hormone Thymosin Alpha-1 works alongside, and serum zinc should be optimized to the upper half of the reference range while maintaining a copper to zinc ratio of approximately one to eight or one to ten to avoid copper depletion. Vitamin D3 combined with K2 is foundational: vitamin D receptors are present on virtually every immune cell, and the vitamin D receptor and toll-like receptor signaling pathways have documented cross-talk. Optimizing D3 to the 50 to 80 nanogram per milliliter range before initiating Thymosin Alpha-1 maximizes the peptide response.

The Mistakes That Undermine Outcomes

The first and most common error is starting without baseline labs. Without a CD4 to CD8 baseline value, there is no data, no N-equals-one experiment, and no way to distinguish response from placebo. The second error is skipping the two-week dose ramp. Beginning immediately at the full 1.6 milligram dose eliminates the ability to identify individual tolerability signals, and two weeks at the conservative 0.5 to 1.0 milligram dose is a clinical intelligence investment, not caution theater. The third is ignoring zinc and vitamin D optimization before initiation. Thymosin Alpha-1 is a signal; the immune cells it activates require micronutrient cofactors. Starting the peptide in a zinc- or D-deficient state is like upgrading software on hardware with dead batteries. The fourth error is using the peptide as a substitute for lifestyle fundamentals. Sleep of less than seven hours of restorative quality chronically suppresses CD4-positive counts measurably. Chronic psychological stress elevates cortisol and drives lymphopenia. Physical inactivity undermines every dimension of immune resilience. The peptide amplifies a healthy substrate; it does not replace one. The fifth error is initiating during an active autoimmune flare. The immunomodulatory mechanism is bidirectional in autoimmune contexts, and active flare is a contraindication, not a therapeutic opportunity.

The N-Equals-One Experimentation Framework

The correct way to run a Thymosin Alpha-1 cycle is as a proper personal clinical trial. Before starting, define the primary endpoint in writing: which biomarker or symptom measure will determine whether this protocol succeeded? Candidates include CD4 to CD8 ratio improvement of at least zero point three, reduction in annual infection episodes by fifty percent or more, or a sustained energy score improvement greater than twenty percent against the baseline. Establish the baseline period by recording infection frequency, energy levels, and recovery times for the three months prior to starting — this becomes the control period against which the intervention is compared. Control the confounding variables ruthlessly. If Thymosin Alpha-1 is added while simultaneously starting a new peptide, changing the sleep protocol, and optimizing vitamin D, the outcome cannot be attributed to any single variable. Document and review at cycle end: what changed, what the labs showed, and whether the change matches the direction and magnitude predicted by the mechanistic hypothesis. Use that review to decide between continuation, dose adjustment, cycle extension, or discontinuation.

Future Research Worth Monitoring

Several open research fronts deserve active attention from serious longevity practitioners. Post-viral immune recovery, particularly after COVID-19 infection, remains an area of active Thymosin Alpha-1 investigation, with multiple papers exploring the peptide's role in immune reconstitution after acute viral insult. Larger randomized controlled trial validation is still needed. The combination of Thymosin Alpha-1 with checkpoint inhibitor cancer therapy is a second frontier: early clinical reports suggest the peptide may modulate immune-related adverse events from PD-1 and PD-L1 inhibitors — a potentially practice-changing application in oncology if confirmed in controlled trials. The third area is thymic regeneration itself. Research into thymic involution reversal, including recent combination trials using growth hormone, dehydroepiandrosterone, and metformin, may eventually pair with Thymosin Alpha-1 for comprehensive thymic axis optimization. None of these applications has yet achieved standard-of-care status, but the trajectory of research is clear.

SECTION SIX · SYNTHESIS

Closing Perspective

The aging of the immune system is not a background process. It is the foreground variable that determines whether the seventh decade of life is characterized by vitality, productivity, and resilience — or by cumulative loss. Thymic involution is measurable, predictable, and, until very recently, untreatable. Thymosin Alpha-1 does not regenerate the thymus. What it does is replace, pharmacologically, the specific signaling function that an aging thymus can no longer perform at full capacity. That distinction matters. This is not magical thinking about reversing aging; it is targeted, evidence-based substitution of a declining endogenous signal with a precisely characterized synthetic analog, executed within a monitored protocol, measured against objective biomarkers, and iterated over quarterly cycles.

For the executive who takes the same disciplined approach to biology as to every other domain of performance, defining the endpoint, establishing the baseline, controlling the variables, measuring the result, Thymosin Alpha-1 represents one of the most mechanistically supported, most thoroughly safety-characterized, and most executable peptide interventions in the current longevity toolkit. The eleven thousand-subject clinical database is not marketing copy. It is earned evidence. The rest is execution.

Where average is not the target.

SECTION SEVEN · CITATIONS

Scientific Reference Library

Every protocol element, dosing parameter, and clinical claim in the preceding article is drawn from the peer-reviewed literature catalogued below. Citations are organized by primary recency, then by supporting mechanistic and clinical context.

PRIMARY STUDIES — WITHIN THREE YEARS

• Simonova MA, Kalinina OV, et al. Aging and Thymosin Alpha-1. International Journal of Molecular Sciences. 2025; 26(23): 11470. PMID 41373628.

• Tao N, Xu X, Ying Y, Hu S, Sun Q, Lv G, Gao J. Thymosin α1 and Its Role in Viral Infectious Diseases: The Mechanism and Clinical Application. Molecules. 2023; 28(8): 3539. PMID 37110771.

• Dinetz E, Lee E. Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials. Alternative Therapies in Health and Medicine. 2024; 30(1): 6–12. PMID 38308608.

• Wu M, Huang Q, Xie Y, et al. Thymosin alpha 1 in cancer therapy: Clinical applications. Expert Opinion on Biological Therapy. 2023; 23(2): 131–146. PMID 36812669.

• Mao L, et al. Thymosin alpha 1: Reimagine its broader applications in the treatment of chronic hepatitis B and beyond. Frontiers in Immunology. 2023; 14: 1095678. PMID 36871535.

SUPPORTING MECHANISTIC AND CLINICAL RESEARCH

• Bozza S, Bistoni F, Gaziano R, et al. Thymosin alpha 1 activates the TLR9/MyD88/IRF7-dependent murine cytomegalovirus sensing for induction of antiviral responses in vivo. International Immunology. 2007; 19(11): 1261–1270. PMID 17804687.

• Romani L, Bistoni F, Gaziano R, et al. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood. 2004; 103(11): 4232–4239. PMID 14982877.

• Yang X, Qian F, He HY, et al. Effect of thymosin alpha-1 on subpopulations of Th1, Th2, Th17, and regulatory T cells in vitro. Brazilian Journal of Medical and Biological Research. 2012; 45(1): 25–32. PMID 22245858.

• Romani L, Moretti S, Fallarino F, et al. Jack of all trades: thymosin α1 and its pleiotropy. Annals of the New York Academy of Sciences. 2012; 1269: 1–6. PMID 23045964.

• Camerini R, Garaci E. Historical review of thymosin alpha 1 in infectious diseases. Expert Opinion on Biological Therapy. 2015; 15 (Supplement 1): S117–S127. PMID 26098768.

• Costantini C, Bellet MM, Pariano M, et al. A reappraisal of thymosin alpha 1 in cancer therapy. Frontiers in Oncology. 2019; 9: 873. PMID 31555601.

• Matteucci C, Grelli S, Balestrieri E, et al. Thymosin alpha 1 and HIV-1: recent advances and future perspectives. Future Microbiology. 2017; 12: 141–155. PMID 28106477.

CLINICAL TRIAL AND CASE SERIES DATA

• He C, Peng W, Li C, Wen TF. Thymalfasin, a promising adjuvant therapy in small hepatocellular carcinoma after liver resection. Medicine (Baltimore). 2017; 96(16): e6606. PMID 28422855.

• Ershler WB, Gravenstein S, Geloo ZS. Thymosin α1 as an adjunct to influenza vaccination in the elderly. Annals of the New York Academy of Sciences. 2007; 1112: 375–384. PMID 17600281.

• Stefanini GF, Foschi FG, Castelli E, et al. Alpha-1-thymosin and transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Hepatogastroenterology. 1998; 45(19): 209–215. PMID 9496515.

• Salvati F, Rasi G, Portalone L, et al. Combined treatment with thymosin-alpha1 and low-dose interferon-alpha after ifosfamide in non-small cell lung cancer: a phase-II controlled trial. Anticancer Research. 1996; 16(2): 1001–1004. PMID 8687090.

REGULATORY AND THYMIC PHYSIOLOGY REFERENCES

• U.S. Food and Drug Administration. 503A Bulks Categories Update for September 2024. FDA.gov.

• Palmer DB. The effect of age on thymic function. Frontiers in Immunology. 2013; 4: 316. PMID 24109481.

• 
  

MEDICAL DISCLAIMER

This content is provided solely for educational and informational purposes and does not constitute medical advice, diagnosis, or treatment. Thymosin Alpha-1 is not an FDA-approved drug for the indications discussed. All clinical information, dosing protocols, and research summaries are presented for educational reference only and do not represent prescribing recommendations or individualized medical guidance. The information in this article should not be used as a substitute for professional medical advice from a licensed physician.

Individuals with pre-existing medical conditions — including but not limited to autoimmune disease, active malignancy, organ transplant, or immunosuppressive therapy — should consult their physician before considering any immune-modulating intervention. Winston's personal results are his own individual experience and are not representative of expected outcomes for all individuals. Always consult a qualified healthcare provider before initiating any new health intervention. Bio Precision Aging does not endorse, prescribe, or provide medical treatment of any kind. Clinical review by Travis Smith, DO — Medical Director, Bio Precision Aging